Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions.

ABSTRACT: FLT3 mutations are present in 30% of newly diagnosed patients with acute myeloid leukemia. Two broad categories of FLT3 mutations are ITD and TKD, with the former having substantial clinical significance. Patients with FLT3-ITD mutation present with a higher disease burden and have inferior overall survival, due to high relapse rates after achieving remission. The development of targeted therapies with FLT3 inhibitors over the past decade has substantially improved clinical outcomes. Currently, two FLT3 inhibitors are approved for use in patients with acute myeloid leukemia: midostaurin in the frontline setting, in combination with intensive chemotherapy; and gilteritinib as monotherapy in the relapsed refractory setting. The addition of FLT3 inhibitors to hypomethylat

SUBMITTER: Fedorov K 

PROVIDER: S-EPMC10136888 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature